Skip to header Skip to main navigation Skip to main content Skip to footer
Scott Lawson
Your next upgrade lives here

Isomorphic Labs Raises 5 Billion Dollars to Push AI-Designed Drugs Toward Human Trials

Demis Hassabis, founder and chief executive of Isomorphic Labs, giving a lecture at EPFL.

Isomorphic Labs, the London-based company that uses artificial intelligence to design new medicines, announced a 5 billion dollar Series C funding round on Tuesday, November 17. The company described the round as oversubscribed. Greenoaks and Sequoia Capital co-led the financing, Andreessen Horowitz joined as a new investor, and Alphabet made an additional significant investment. All of the company's existing investors also took part, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

Isomorphic was spun out of Google DeepMind in 2021 and is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland. It is led by its founder and chief executive, Sir Demis Hassabis, and its president, Max Jaderberg. Hassabis, now chairman of Google DeepMind and chief scientist of Alphabet, shared the 2024 Nobel Prize in Chemistry with John Jumper for AlphaFold, the system that predicts the structure of proteins from their genetic sequence.

The company's drug-design engine, called IsoDDE, combines foundational simulation models that work across many areas of chemistry and biology. The system is designed to explore vast chemical spaces, propose candidate molecules and refine them for properties a medicine needs, such as binding to the right target, remaining stable and reaching the intended tissue. The company says its models are moving predictions closer to experimental accuracy, although those claims have not yet been validated by an approved medicine.

The new capital is earmarked for four priorities: maturing IsoDDE and building new foundational biology models, expanding a partner ecosystem focused on how diseases work, building global infrastructure for AI-led bioengineering, and creating the translational and clinical development capability needed to test candidates in people. Isomorphic reports positive preclinical results in its internal oncology and immunology programs and in partnered work, and it lists Eli Lilly, Novartis and Johnson & Johnson as pharmaceutical partners.

The scale of the round is striking. It follows a 600 million dollar first external round in March 2025 and a 2.1 billion dollar Series B in May 2026, bringing external funding to about 7.7 billion dollars across three rounds. Trade coverage citing BioSpace described it as the largest venture round in biotech history, ahead of the 3 billion dollars Altos Labs raised in 2022. Isomorphic did not disclose a valuation; Bloomberg reported talks at roughly a 50 billion dollar valuation, which the company has not confirmed.

In the announcement, Hassabis said the founding conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI, and that the round would help drive the company's first therapeutic programs towards clinical trials. That next step is also the hardest test. Isomorphic has not yet disclosed a human trial, a named first clinical candidate or a specific trial date. Hassabis said at Davos in January that the first clinical trials were expected to begin by the end of 2026, and the funding announcement did not update that target.

That gap matters because designing a promising molecule is only the first stage of drug development. Analyses cited in coverage of the raise note that roughly nine in ten candidates that enter clinical development fail, most often because they do not work in patients or prove too toxic, and no AI-designed drug has yet won U.S. Food and Drug Administration approval. The 5 billion dollars buys the expensive infrastructure to move from computation into human testing. What will settle the argument is a registered first-in-human trial, published data and, eventually, results in patients.

Photo: Demis Hassabis at EPFL in May 2023. Photograph by Alain Herzog, Mediathèque EPFL, CC BY-SA, via Wikimedia Commons.

Artificial Intelligence
Biotech
Startups
Venture Capital
Innovation
Technology
Google

Copyright © 2026 Rocky Mountain Madman LLC - All rights reserved

Developed and Designed by Rocky Mountain Madman LLC